chronic inflammatory demyelinating polyneuropathy (CIDP) is no exception. Although CIDP is a rare disease, it has been growing in prevalence. Chronic inflammatory demyelinating polyneuropathy is a rare autoimmune disorder wherein the body’s immune system attacks the myelin causing various symptoms such as numbness, weakness, and a lack of certain reflexes.
Various new drugs have been launched into the market after recent FDA approvals which also boosts the growth of the global chronic inflammatory demyelinating polyneuropathy market encouraging the growth of the market include surging awareness about the disease and government endeavors regarding the same.
The Chronic Inflammatory Demyelinating Polyneuropathy Market is due to register growth at a CAGR of 6.2% result in a market value of USD 3907.17 Mn by the end of the assessment period in 2023.
Get Free Sample Here https://www.marketresearchfuture.com/sample_request/6947
Major Key Players Competitive Dashboard:
Numerous players are operating in the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market. Some of the big players have captured a significant share in the global market, taking advantage of their strong position and presence in the number of countries and regions across the world.
The Prominent competitors include –
Kedrion S.p.A
Octapharma
CSL Behring
Pfizer Inc
Shire
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals
Baxter
Bio Products Laboratory Ltd.
Grifols
Teijin Pharma Limited.
Market Segmentation
The structure which has been determined by various components in MRFR’s report has been segmented on the basis of treatment & diagnosis, route of administration, end-user, and region.
Market Segmentation
The market structure which has been determined by various components in MRFR’s report has been segmented on the basis of treatment & diagnosis, route of administration, end-user, and region. Treatment and diagnosis of chronic inflammatory demyelinating polyneuropathy have been segmented into treatment and diagnosis. The treatment segment which holds the most significant share of the market is sub-segmented into corticosteroids, intravenous immunoglobin (IVIG), plasmapheresis (plasma exchange), physiotherapy, and others. The treatment segment is also growing at the highest CAGR of 6.32% during the review period due to rising demand for effective treatments for CIDP. Among the various sub-segments, the IVIG sub-segment has achieved a leadership status due to the preference for IVIG as the first line of treatment for CIDP.
Route of administration of chronic inflammatory demyelinating polyneuropathy medication has been segmented into oral, intravenous, and others. Due to the high preference for IVIG treatment which enters the bloodstream directly to react faster, the intravenous segment by route of administration has both acquired the largest share of the market and is growing at the highest CAGR during the forecast period. The intravenous segment accounts for 85% of the total market share, followed by oral and others.
End-users in the chronic inflammatory demyelinating polyneuropathy market have been segmented into specialty neurological clinics, hospitals, research & academic laboratories, and others. Hospitals have amassed a 49% share of the global market due to their widespread presence and the preference for hospitals among patients. However, patients are increasingly seeing the value in specialty clinics where they may understand their illness better. As a result, the specialty neurological clinics segment is growing at the most rapid CAGR of 6.49% during the review period.
Access Complete 124 Pages Premium Research Enabled with Detailed Table of Content at https://www.marketresearchfuture.com/reports/chronic-inflammatory-demyelinating-polyneuropathy-market-6947
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Rising Prevalence Of Autoimmune Diseases
5.2.2 Increasing Research And Development Related To Plasma-Derived Medicines
5.2.3 Increasing Awareness About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.3 Restraints
5.3.1 Side-Effects Associated With The Intravenous Immunoglobulin (IVIG) Treatment
5.3.2 High Cost Of The IVIG Treatment
5.4 Opportunity
5.4.1 Advancements In The Treatment
5.5 Clinical Trials Data
Chronic Inflammatory Demyelinating Polyneuropathy Market Regional Analysis
The regional segmentation of the Chronic inflammatory demyelinating polyneuropathy market covers regions such as The Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA). The Asia Pacific is anticipated to be the fastest growing regional market. It has been anticipated to witness huge growth at 7.03% CAGR due to rapid urbanization, steadily rising technological advancement, and improving medical facilities.
10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Republic Of Korea
10.4.6 Rest Of Asia Pacific
10.5 Middle East And Africa
10.5.1 Middle East
10.5.2 Africa
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Email: sales@marketresearchfuture.com
Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/chronic-inflammatory-demyelinating-polyneuropathy-market-6947